Thoughts on the neuroplasticity potential of PE 22-28
Posted by vik_b in Research & News - 7 points, 0 comments.
I was reading up on some of the newer preclinical work regarding PE 22-28 and the way it targets TREK-1 channels. It is pretty wild how much interest there is in peptides that can act as fast-acting antidepressants compared to the slow crawl of traditional SSRIs. The idea of blocking those potassium channels to trigger synaptogenesis sounds like a massive leap for neuroplasticity research.
Not gonna lie, I find the speed of action in these animal models very promising, but I am also a bit skeptical about how this translates to humans. Most of what we see is still in the early stages and we really dont know the safety profile for long-term use yet. I have always been interested in cognitive peptides, but the jump from a lab setting to actual human mood regulation is huge.
It makes me wonder if we are moving toward a future where we can actually repair neural pathways rather than just managing symptoms. Has anyone else been following the spadin-derived research? Do you think the risk of unknown side effects is worth the potential for such a rapid shift in neurogenesis? ⚡
Community discussion - research and educational context only. Not medical advice.